Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.
A total of 20 patients with neurofibromatosis 1 (NF1) were screened for NF1-related osteoporosis, and blood samples were collected for isolation of peripheral blood osteoclast progenitors. Patients with NF1 had higher levels of serum bone turnover markers (CTX and PINP) compared to controls. In addition, persons with high bone resorption in vitro on average had high levels of serum CTX. Of the 20 patients with NF1, 15 had low bone mineral density (osteopenia/osteoporosis), but these 15 patients did not have marked risk factors for low bone mineral density. Thus, we recommend screening for osteoporosis to all adult patients with NF1. Our aim was also to characterize the effects of bisphosphonates on NF1 osteoclasts in vitro. NF1 osteoclasts and osteoclasts from healthy controls in vitro were treated with zoledronic acid, alendronate and clodronate. These bisphosphonates caused a marked reduction in the number of normal control osteoclasts in vitro, while only a slight change was observed in the number of NF1 osteoclasts. Ras-inhibitor FTS counteracted this NF1-related insensitivity to zoledronic acid, suggesting that Ras may play a role in this phenomenon.
University of Turku, Department of Cell Biology and Anatomy, Turku 20520, Finland.
Eetu
E
Heervä
Sirkku
S
Peltonen
Erkki
E
Svedström
Hannu T
HT
Aro
Kalervo
K
Väänänen
Juha
J
Peltonen
D000328:Adult; D000368:Aged; D019386:Alendronate / Q000494:pharmacology; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000502:physiology*; D001862:Bone Resorption / Q000097:blood / Q000473:pathology*; D002478:Cells, Cultured; D004002:Clodronic Acid / Q000494:pharmacology; D004164:Diphosphonates / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D008159:Lumbar Vertebrae / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009456:Neurofibromatosis 1 / Q000097:blood / Q000150:complications / Q000473:pathology*; D010010:Osteoclasts / Q000187:drug effects* / Q000473:pathology; D010024:Osteoporosis / Q000097:blood / Q000150:complications / Q000473:pathology; D000077211:Zoledronic Acid
D015415:Biomarkers; D004164:Diphosphonates; D007093:Imidazoles; D004002:Clodronic Acid; D000077211:Zoledronic Acid; D019386:Alendronate